DD222305A5 - Verfahren zur herstellung von 2-alkylthio-1-aminoalkyl-2-pyrrolin-3-carbonitrile - Google Patents
Verfahren zur herstellung von 2-alkylthio-1-aminoalkyl-2-pyrrolin-3-carbonitrile Download PDFInfo
- Publication number
- DD222305A5 DD222305A5 DD84262957A DD26295784A DD222305A5 DD 222305 A5 DD222305 A5 DD 222305A5 DD 84262957 A DD84262957 A DD 84262957A DD 26295784 A DD26295784 A DD 26295784A DD 222305 A5 DD222305 A5 DD 222305A5
- Authority
- DD
- German Democratic Republic
- Prior art keywords
- pyrroline
- carbonitrile
- oxo
- general formula
- animals
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 6
- 230000008569 process Effects 0.000 title claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 22
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 abstract description 9
- 239000000203 mixture Substances 0.000 abstract description 5
- 239000002253 acid Substances 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 238000011321 prophylaxis Methods 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 230000001732 thrombotic effect Effects 0.000 abstract description 2
- 239000003705 antithrombocytic agent Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- 239000000126 substance Substances 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- -1 pyrrolidino, Piperidino- Chemical class 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 239000002585 base Substances 0.000 description 11
- 230000037396 body weight Effects 0.000 description 11
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 10
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 239000000725 suspension Substances 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- 210000002683 foot Anatomy 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 239000012312 sodium hydride Substances 0.000 description 6
- 229910000104 sodium hydride Inorganic materials 0.000 description 6
- 229920003091 Methocel™ Polymers 0.000 description 5
- 208000025865 Ulcer Diseases 0.000 description 5
- 230000036760 body temperature Effects 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 5
- 229960000905 indomethacin Drugs 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 description 5
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 5
- 231100000397 ulcer Toxicity 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000005804 alkylation reaction Methods 0.000 description 4
- 230000001754 anti-pyretic effect Effects 0.000 description 4
- 239000000010 aprotic solvent Substances 0.000 description 4
- 235000010418 carrageenan Nutrition 0.000 description 4
- 229920001525 carrageenan Polymers 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000007059 acute toxicity Effects 0.000 description 3
- 231100000403 acute toxicity Toxicity 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 230000029936 alkylation Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 2
- VFLQQZCRHPIGJU-UHFFFAOYSA-N 1-(2-chloroethyl)piperidine;hydron;chloride Chemical compound Cl.ClCCN1CCCCC1 VFLQQZCRHPIGJU-UHFFFAOYSA-N 0.000 description 2
- AHVVVRDSNYZYFZ-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-5-oxo-4,4-diphenyl-2-propan-2-ylsulfanylpyrrole-3-carbonitrile Chemical compound O=C1N(CCCN(C)C)C(SC(C)C)=C(C#N)C1(C=1C=CC=CC=1)C1=CC=CC=C1 AHVVVRDSNYZYFZ-UHFFFAOYSA-N 0.000 description 2
- CJHDGDUAGLJUPY-UHFFFAOYSA-N 2-ethylsulfanyl-5-oxo-1-(2-piperidin-1-ylethyl)-4,4-dipyridin-2-ylpyrrole-3-carbonitrile Chemical compound CCSC1=C(C#N)C(C=2N=CC=CC=2)(C=2N=CC=CC=2)C(=O)N1CCN1CCCCC1 CJHDGDUAGLJUPY-UHFFFAOYSA-N 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- HNUALPPJLMYHDK-UHFFFAOYSA-N C[CH]C Chemical compound C[CH]C HNUALPPJLMYHDK-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001741 anti-phlogistic effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 229920006158 high molecular weight polymer Polymers 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000003586 protic polar solvent Substances 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000002408 ulcerprotective effect Effects 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- WWKHOLGVGCCHGG-UHFFFAOYSA-N 1-[2-(diethylamino)ethyl]-5-oxo-4,4-diphenyl-2-propan-2-ylsulfanylpyrrole-3-carbonitrile Chemical compound N#CC1=C(SC(C)C)N(CCN(CC)CC)C(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 WWKHOLGVGCCHGG-UHFFFAOYSA-N 0.000 description 1
- FPDMTOMLRNRHRN-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-2-ethylsulfanyl-5-oxo-4,4-diphenylpyrrole-3-carbonitrile;hydrochloride Chemical compound Cl.O=C1N(CCCN(C)C)C(SCC)=C(C#N)C1(C=1C=CC=CC=1)C1=CC=CC=C1 FPDMTOMLRNRHRN-UHFFFAOYSA-N 0.000 description 1
- BCQYQCBYYNXHIG-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-5-oxo-4,4-diphenyl-2-propylsulfanylpyrrole-3-carbonitrile;hydrochloride Chemical compound Cl.O=C1N(CCCN(C)C)C(SCCC)=C(C#N)C1(C=1C=CC=CC=1)C1=CC=CC=C1 BCQYQCBYYNXHIG-UHFFFAOYSA-N 0.000 description 1
- YMDNODNLFSHHCV-UHFFFAOYSA-N 2-chloro-n,n-diethylethanamine Chemical compound CCN(CC)CCCl YMDNODNLFSHHCV-UHFFFAOYSA-N 0.000 description 1
- FQRZVEABMHCOQU-UHFFFAOYSA-N 2-ethylsulfanyl-5-oxo-4,4-diphenyl-1h-pyrrole-3-carbonitrile Chemical compound O=C1NC(SCC)=C(C#N)C1(C=1C=CC=CC=1)C1=CC=CC=C1 FQRZVEABMHCOQU-UHFFFAOYSA-N 0.000 description 1
- STKWICSNFDLOJO-UHFFFAOYSA-N 2-methylsulfanyl-1-(3-morpholin-4-ylpropyl)-5-oxo-4,4-diphenylpyrrole-3-carbonitrile Chemical compound CSC1=C(C#N)C(C=2C=CC=CC=2)(C=2C=CC=CC=2)C(=O)N1CCCN1CCOCC1 STKWICSNFDLOJO-UHFFFAOYSA-N 0.000 description 1
- RIGWVWIQEXVOSI-UHFFFAOYSA-N 2-methylsulfanyl-5-oxo-4,4-diphenyl-1-(2-pyrrolidin-1-ylethyl)pyrrole-3-carbonitrile Chemical compound CSC1=C(C#N)C(C=2C=CC=CC=2)(C=2C=CC=CC=2)C(=O)N1CCN1CCCC1 RIGWVWIQEXVOSI-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- NYYRRBOMNHUCLB-UHFFFAOYSA-N 3-chloro-n,n-dimethylpropan-1-amine Chemical compound CN(C)CCCCl NYYRRBOMNHUCLB-UHFFFAOYSA-N 0.000 description 1
- LJQNMDZRCXJETK-UHFFFAOYSA-N 3-chloro-n,n-dimethylpropan-1-amine;hydron;chloride Chemical compound Cl.CN(C)CCCCl LJQNMDZRCXJETK-UHFFFAOYSA-N 0.000 description 1
- XQLBAXXPUXQZRZ-UHFFFAOYSA-N 5-oxo-4,4-diphenyl-2-propan-2-ylsulfanyl-1h-pyrrole-3-carbonitrile Chemical compound O=C1NC(SC(C)C)=C(C#N)C1(C=1C=CC=CC=1)C1=CC=CC=C1 XQLBAXXPUXQZRZ-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000001262 anti-secretory effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/38—2-Pyrrolones
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19833317653 DE3317653A1 (de) | 1983-05-14 | 1983-05-14 | 2-alkylthio-1-aminoalkyl-2-pyrrolin-3-carbonitrile, verfahren zu deren herstellung sowie deren verwendung bei der prophylaxe und therapie thrombotischer zustaende |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DD222305A5 true DD222305A5 (de) | 1985-05-15 |
Family
ID=6199021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DD84262957A DD222305A5 (de) | 1983-05-14 | 1984-05-11 | Verfahren zur herstellung von 2-alkylthio-1-aminoalkyl-2-pyrrolin-3-carbonitrile |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US4499089A (enExample) |
| EP (1) | EP0125684B1 (enExample) |
| JP (1) | JPS59212469A (enExample) |
| AT (1) | ATE28189T1 (enExample) |
| AU (1) | AU2798884A (enExample) |
| CS (1) | CS244815B2 (enExample) |
| DD (1) | DD222305A5 (enExample) |
| DE (2) | DE3317653A1 (enExample) |
| DK (1) | DK239084A (enExample) |
| ES (3) | ES532438A0 (enExample) |
| GR (1) | GR82094B (enExample) |
| HU (1) | HUT34158A (enExample) |
| SU (1) | SU1251800A3 (enExample) |
| YU (1) | YU83284A (enExample) |
| ZA (1) | ZA843615B (enExample) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL176372B (nl) * | 1952-02-26 | Salvat Editores | Werkwijze voor het bereiden van drukinkt alsmede werkwijze voor het bereiden van een preparaat om aan drukinkt te worden toegevoegd. | |
| FI59246C (fi) * | 1974-06-24 | 1981-07-10 | Otsuka Pharma Co Ltd | Foerfarande foer framstaellning av benscykloamidderivat anvaendbara vid trombos- och emboliterapin |
| NZ182264A (en) * | 1975-10-25 | 1979-01-11 | Beecham Group Ltd | 2-carboxyalkyl-1-hydroxyalkyl-pyrrolidin-3,5-dione or-piperidin-3,6-dione derivatives prarmaceutical compostions |
| US4329347A (en) * | 1978-02-17 | 1982-05-11 | Boehringer Ingelheim Gmbh | Cardiotonic and antithrombotic sulfur-containing derivatives of carbostyril |
| DK75779A (da) * | 1978-03-13 | 1979-09-14 | Du Pont | 4,5-diaryl-2- (substitueret thio) pyrroler og sulfoxider og sulfoner deraf samt fremgangsmaader til deres fremstilling og anvendelse |
| DE3212591A1 (de) * | 1982-04-03 | 1983-10-13 | Gödecke AG, 1000 Berlin | 2-pyrrolin-3-carbonitril-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel |
-
1983
- 1983-05-14 DE DE19833317653 patent/DE3317653A1/de not_active Ceased
-
1984
- 1984-05-04 CS CS843308A patent/CS244815B2/cs unknown
- 1984-05-10 GR GR74677A patent/GR82094B/el unknown
- 1984-05-10 US US06/608,828 patent/US4499089A/en not_active Expired - Fee Related
- 1984-05-11 HU HU841851A patent/HUT34158A/hu unknown
- 1984-05-11 DD DD84262957A patent/DD222305A5/de unknown
- 1984-05-11 JP JP59093126A patent/JPS59212469A/ja active Pending
- 1984-05-11 YU YU00832/84A patent/YU83284A/xx unknown
- 1984-05-11 SU SU843737938A patent/SU1251800A3/ru active
- 1984-05-11 ES ES532438A patent/ES532438A0/es active Granted
- 1984-05-11 ES ES532445A patent/ES532445A0/es active Granted
- 1984-05-11 ES ES532446A patent/ES8502421A1/es not_active Expired
- 1984-05-14 AU AU27988/84A patent/AU2798884A/en not_active Abandoned
- 1984-05-14 EP EP84105457A patent/EP0125684B1/de not_active Expired
- 1984-05-14 DK DK239084A patent/DK239084A/da not_active Application Discontinuation
- 1984-05-14 ZA ZA843615A patent/ZA843615B/xx unknown
- 1984-05-14 DE DE8484105457T patent/DE3464601D1/de not_active Expired
- 1984-05-14 AT AT84105457T patent/ATE28189T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE3464601D1 (en) | 1987-08-13 |
| ES532446A0 (es) | 1985-01-01 |
| ES8502867A1 (es) | 1985-02-01 |
| EP0125684B1 (de) | 1987-07-08 |
| ZA843615B (en) | 1984-12-24 |
| CS244815B2 (en) | 1986-08-14 |
| ES532438A0 (es) | 1985-02-01 |
| ES8502868A1 (es) | 1985-02-01 |
| DK239084A (da) | 1984-11-15 |
| HUT34158A (en) | 1985-02-28 |
| ES532445A0 (es) | 1985-02-01 |
| SU1251800A3 (ru) | 1986-08-15 |
| ATE28189T1 (de) | 1987-07-15 |
| DK239084D0 (da) | 1984-05-14 |
| EP0125684A1 (de) | 1984-11-21 |
| ES8502421A1 (es) | 1985-01-01 |
| AU2798884A (en) | 1984-11-15 |
| GR82094B (enExample) | 1984-12-13 |
| JPS59212469A (ja) | 1984-12-01 |
| YU83284A (en) | 1986-10-31 |
| DE3317653A1 (de) | 1984-11-15 |
| CS330884A2 (en) | 1985-09-17 |
| US4499089A (en) | 1985-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69813815T2 (de) | Hydrazinderivate | |
| DE69128145T2 (de) | 1,2,5,6-tetrahydro-1-methylpyridine, ihre herstellung und anwendung | |
| EP0072932A2 (de) | Neue Piperazinone, ihre Herstellung und Verwendung | |
| EP0058975B1 (de) | Substituierte N-(4-Indolyl-piperidino-alkyl)-benzimidazolone, Verfahren zu ihrer Herstellung und ihre Verwendung als Pharmazeutika | |
| DE2238504B2 (de) | l-Phenoxy-3-alkylaminopropan-2-ol -Derivate | |
| DE1670536B2 (de) | Neue 2-Anilino-5-acylamino-pyrimidlne | |
| EP0000220B1 (de) | Dihydrouracile, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel | |
| DE2012138A1 (de) | Neue Pyrazinderivate und diese enthaltende pharmazeutische Präparate | |
| DE2166381C3 (de) | γ-Piperidinobutyrophenonderivate, Verfahren zu i hrer Herstellung und Arzneipräparate | |
| DE2847792C2 (enExample) | ||
| DD201903A5 (de) | Verfahren zur herstellung von derivaten des thienopyridonons | |
| EP0261478B1 (de) | Neue Derivate von 4,5-Dihydro-oxazolen, Verfahren zu ihrer Herstellung und ihre Verwendung | |
| DE68912263T2 (de) | 4-Methyl-5[2-(4-phenyl-1-piperazinyl)-ethyl]-Thiazolderivate, ihre Herstellung und Zusammenstellungen, die sie enthalten. | |
| DE2617955A1 (de) | Neue l-substituierte -aroyl-4-hydroxypiperidine, verfahren zu ihrer herstellung und sie enthaltende arzneimittel | |
| DE1200831B (de) | Verfahren zur Herstellung von Thioxanthenderivaten | |
| DE69826881T2 (de) | Neue indolcarboxamide, pharmazeutische zusammensetzungen und methoden zur hemmung von calpain | |
| DE2513136C3 (de) | N-(1-Benzylpiperid-4-yl)-benzamide, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate | |
| EP0125684B1 (de) | 2-Alkylthio-1-aminoalkyl-2-pyrrolin-3-carbonitrile, Verfahren zu deren Herstellung sowie diese enthaltende Arzneimittel für die Prophylaxe und Therapie thrombotischer Zustände | |
| DE2757766A1 (de) | 1-substituierte-3-aminoaethoxypyrrolidine, ihre herstellung und verwendung als blutdrucksenkendes mittel | |
| EP0091045B1 (de) | 2-Pyrrolin-3-carbonitril-Derivate, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel | |
| DE2245061A1 (de) | Derivate des adenins | |
| DE2912026C2 (enExample) | ||
| DE2228216C3 (de) | 5-Acylaminotetrazole und Verfahren zu deren Herstellung | |
| DE2636723A1 (de) | Pyrrolin-3-on-2-derivate | |
| DE2017902C3 (de) | Benzothiopyranverbindungen, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel |